Phosphate Research – IMPHOS http://imphos.org/ Mon, 21 Nov 2022 04:20:54 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://imphos.org/wp-content/uploads/2021/08/IMPHOS-icon-150x150.jpg Phosphate Research – IMPHOS http://imphos.org/ 32 32 Chinese giant Battey Gotion opens third overseas factory in Vietnam https://imphos.org/chinese-giant-battey-gotion-opens-third-overseas-factory-in-vietnam/ Mon, 21 Nov 2022 04:20:54 +0000 https://imphos.org/chinese-giant-battey-gotion-opens-third-overseas-factory-in-vietnam/ (Yicai Global) Nov. 21 – Construction work has started on Gotion High-tech’s third overseas factory in Vietnam, which is also the Southeast Asian country’s first lithium iron phosphate battery factory. . Covering an area of ​​14 hectares, the $275 million project began construction on November 18, the Volkswagen-backed company announced on its official WeChat account […]]]>

(Yicai Global) Nov. 21 – Construction work has started on Gotion High-tech’s third overseas factory in Vietnam, which is also the Southeast Asian country’s first lithium iron phosphate battery factory. .

Covering an area of ​​14 hectares, the $275 million project began construction on November 18, the Volkswagen-backed company announced on its official WeChat account on November 19. Gotion will own a 51% stake in the factory and Vietnam’s largest private company, VinGroup. and his automotive startup VinFast the remaining 49%.

The first phase of the project, which will have a generating capacity of 5 gigawatt hours, is expected to come into service late next year and begin mass production in the third quarter of 2024. The batteries at the plant will meet the demand for the new energy of VinFast. Vehicles.

VinFast partnered with Gotion on lithium iron phosphate batteries in August 2021. Last month, it partnered with Gotion Contemporary rival Amperex Technology on cell-to-pack technology and smart frame skateboard projects integrated from CATL.

Founded in 2017, VinFast acquired General Motors’ vehicle production line in Vietnam in 2018 and retained most of GM’s employees. VinFast is known as the Tesla of Vietnam.

Hefei, Gotion, based in Anhui province, mainly produces lithium iron phosphate batteries. It plans to reach 300 GWh of lithium battery production capacity by 2025. A third of the total will be overseas capacity, mostly from plants in Europe, North America and South Asia. South East.

In the first nine months of the year, Gotion’s battery installation capacity was 9.9 GWh, ranking eighth in the world with a market share of 2.9%, according to company data. of research SNE Research.

Gotion’s actions [SHE: 002074] were trading little changed at 32.59 CNY (4.55 USD) at 10:30 am today.

Publisher: Futura Costaglione

]]>
The Global Fertilizer Blends Market Size to Attend the Highest CAGR https://imphos.org/the-global-fertilizer-blends-market-size-to-attend-the-highest-cagr/ Fri, 18 Nov 2022 04:15:00 +0000 https://imphos.org/the-global-fertilizer-blends-market-size-to-attend-the-highest-cagr/ Global Fertilizer Blends Market *** Report: Global Fertilizer Blends Market Research Analysis, Size, Demand and Forecast 2022-2028 Global Fertilizer Blends Market 2022 Industry Analysis, Regional Survey and Forecast Report: Supply, Demand, Suppliers, Porter’s Five Forces Analysis, Segment Trends, Statistical Survey, Price Analysis, Geographical Exploration, Revenue, Historical Data & Projection The purpose of this Fertilizer Blends […]]]>

Global Fertilizer Blends Market

*** Report: Global Fertilizer Blends Market Research Analysis, Size, Demand and Forecast 2022-2028

Global Fertilizer Blends Market 2022 Industry Analysis, Regional Survey and Forecast Report: Supply, Demand, Suppliers, Porter’s Five Forces Analysis, Segment Trends, Statistical Survey, Price Analysis, Geographical Exploration, Revenue, Historical Data & Projection The purpose of this Fertilizer Blends market exploration report is to characterize, break down, split and estimate the Fertilizer Blends showcase size based on types, applications, end customers, key districts and key players. The trending players competing in the market are Henan Xinlianxin Fertilizer, DAYAL GROUP, Agrichem do Brasil SA, Sumitomo Chemical, HJ Baker & Bro, Beijing Xinhefeng Agrochemical, The Mosaic Company, Compass Minerals, Compass Minerals, Coromandel International Limited, Bayer CropScience AG , Gujarat State Fertilizers & Chemicals Ltd.

*** Read the full detailed report @ https://www.zionmarketresearch.com/report/fertilizer-mixtures-market

This report gives the global fertilizer blends market size in key topographies viz. Europe, North America, Asia-Pacific, Central and South America, Middle East and Africa, with a focus on major economies such as Canada, USA, Mexico, UK, India. Germany, Spain, France, Russia, Italy, India and China, South Korea, Japan, Southeast Asia, Indonesia, Australia, Argentina, Brazil, South Africa, GCC countries, Turkey and Egypt among other notable nations in the rest of the world. The report focuses on the fertilizer blend offerings in the previously mentioned districts/nations. This exploration report organizes the global Fertilizer Blends showcase study by top brands/players/vendors, types, applications, end-users, regions, and countries. This research study assesses the global Fertilizer Blends market share, growth rate, player market shares, player positioning, projection trends, competition landscape, market drivers, challenges and opportunities, price analysis, deployment channels and distributors. Setting up the fertilizer blends showcase is also referenced in the report, which can enable clients to apply essential strategies to gain the upper hand. Such a thorough and in-depth research investigation yields fundamental development with key propositions and unbiased quantifiable scrutiny.

*** Our free sample report includes:

* 2022 Updated Report Introduction, Industry Overview and In-Depth Analysis
* 110+ page research report (including updated research)
* Provide guidance by chapter on demand
* Regional analysis updated in 2022 with graphical representation of size,
Share & Trends
* Includes an updated list of tables and figures
* The updated report includes top market players with their business strategies,
Sales volume and revenue analysis
* Zion Market Research Methodology

***Download an exclusive PDF sample report for FREE: https://www.zionmarketresearch.com/sample/fertilizer-mixtures-market

Don’t miss out on business opportunities in the Fertilizer Blends Market. Talk to our analyst and get crucial industry insights that will help your business grow.

This can be used to enhance the current position and structure future expansions in a particular area of ​​the fertilizer blends showcase.

*** The report also assesses the inclinations of the market as well as the mechanical advancements of the business.

Market Size Segment By Type:- Nitrogen Phosphorus Potassium Fertilizers, Nitrogen & Phosphate Fertilizer Blends, Hydrogenated Orthophosphate, Nitrogen & Phosphorus Fertilizer Blends, and Phosphorus & Potassium Fertilizers

Market Size Segmentation by End-User:- Soil Quality and Agricultural Production

*** The study objectives of this industry report study are valuable for:-

–To assess and analyze the global Fertilizer Blends market size (value & volume) by company, key regions, countries, products, type, technologies, applications, and end-user, historical data breakdown, and forecast data to 2028 .
— To understand the structure of Fertilizer Blends market by identifying its various subsegments.
–Share in-depth information on key factors influencing market growth (growth potential, opportunities, drivers, trends, industry-specific challenges, and risks).
–Focuses on the key global Fertilizer Mixtures companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent developments.
— To project the sales value and volume of Fertilizer Blends submarkets, with respect to key regions and countries.
–Analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
–This report includes market size estimation for value (USD Million) and volume. Both top-down and bottom-up approaches have been taken to estimate and validate the market size of Fertilizer Blends market, to estimate the size of various other dependent submarkets in the parent market.
–Major market players have been identified through secondary research and their market shares have been determined through primary and secondary research. All percentage shares are divided and breakdowns were determined using secondary sources and verified primary interviews and surveys.
— New market entry, marketing, product portfolio expansion, sales channels, and pricing, among other business strategies, can be implemented using this report

Get a request to buy this report: https://www.zionmarketresearch.com/inquiry/fertilizer-mixtures-market

Following are the Chapters to view the Global Fertilizer Blends Market:-

Division 1:

Represents Fertilizer Blends definition, specification and classification, Fertilizer Blends applications and market segment by regions.

Division 2:

Break down the Suppliers and Raw Material, Fertilizer Blends manufacturing process, industry chain structure, manufacturing cost structure.

Division 3:

To determine blended fertilizer manufacturing plants and blended fertilizer technical data analysis, capacity and commercial production date, R&D status, manufacturing plant distribution, analysis sources of raw materials and the technological source

Section 4:

To demonstrate the Overall Fertilizer Blends Market Analysis, Sales Analysis (Company Segment), Capacity Analysis (Company Segment), Sales Price Analysis (Company Segment) of the company)

Items 5:

To demonstrate regional market analysis that incorporates North America, Europe, China, and Japan, Fertilizer Blends Segment Market Analysis (by Type)

Items 6:

Break Down the Fertilizer Blends Segment Market Analysis (by Application) Fertilizer Blends major manufacturers analysis.

Clause 7:

Fertilizer Blends Market Trend Analysis, Regional Market Trend, Market Trend by Product Type, Market Trends by Application.

Section 8:

Regional Marketing Type Analysis, Supply Chain Analysis, International Trade Type Analysis by Fertilizer Blends market.

Section 9:

To investigate consumer analysis and SWOT analysis of global Fertilizer Blends markets.

Clause 10:

To describe Fertilizer Blends offers channel, wholesalers, brokers, merchants, research findings and results, index and information source.

Read our other reports:

https://www.openpr.com/news/2812070/global-inorganic-base-market-by-growth-industry-size-trends

https://www.openpr.com/news/2812054/global-composite-adhesives-market-size-by-growth-rate-business

https://hackmd.io/z961KMUNRvGNAXXoRTd4kQ
https://hackmd.io/GijCrxoCSAe4DQTgdGaiyw
https://hackmd.io/8vEjV0X-QmSXXpowe1lyZA
https://hackmd.io/GiXucIrsR1OOtIlfUq6sIg
https://hackmd.io/@saadmaraqa81/Hk6cqamQi
https://hackmd.io/@saadmaraqa81/HylD007mj

Contact us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, USA
Tel: +1 (844) 845-5245
Email: sales@zionmarketresearch.com

our expertise

At Zion Market Research, we have built our team with industry analysts, domain experts, and consultants, who leverage their global experience to help us deliver excellence in every project we undertake. Zion Market Research publishes over 100 market research reports that provide data covering the following aspects:

Market research
Market sizing and forecasts
Industry Entry Strategies
Niche Market Trends
New sustainability trends
Innovation trends
Knowledge of the customer
Distribution channel assessment
Primary interviews
Consumer surveys
Secondary research

This press release was published on openPR.

]]>
Anti-Caking Agents Market Expected to Reach $2.1 Billion https://imphos.org/anti-caking-agents-market-expected-to-reach-2-1-billion/ Tue, 15 Nov 2022 05:45:00 +0000 https://imphos.org/anti-caking-agents-market-expected-to-reach-2-1-billion/ Anti-Caking Agents Market According to a new report published by Allied Market Research, titled “Global Anti-Caking Agents Market”, the global anti-caking agents market size was valued at $1.1 billion in 2021 and is expected to reach $2.1 billion. dollars by 2031, growing at a CAGR of 6.4% from 2022 to 2031. Request a free sample […]]]>

Anti-Caking Agents Market

According to a new report published by Allied Market Research, titled “Global Anti-Caking Agents Market”, the global anti-caking agents market size was valued at $1.1 billion in 2021 and is expected to reach $2.1 billion. dollars by 2031, growing at a CAGR of 6.4% from 2022 to 2031.

Request a free sample report: https://www.alliedmarketresearch.com/request-sample/600

Anti-caking agents are substances that are added in small amounts to meals, cosmetics, and other items to prevent them from clumping and sticking. Anti-caking compounds are used to prevent the formation of lumps, usually in fine powder materials. Alcohol, water, and other organic solvents can all be used to dissolve anti-caking compounds. They absorb extra moisture or cover the powder particles with something that repels water. The high flexibility of anti-caking agents is expected to further drive the demand for the anti-caking agents market over the forecast period. The demand for anti-caking compounds is also expected to increase due to factors such as ease of packaging, transportation and consumption. Rising demand from a number of industries including food, feed and fertilizer sectors is expected to drive the growth of the global anti-caking agents market. The major factors driving the global anti-caking agents market are increasing demand for packaged foods and increasing disposable income.

Anti-caking chemicals are used in food and beverages due to growing customer demand for take-out, fast food, and processed foods. Powdered cellulose tricalcium phosphate, sodium bicarbonate, polydimethylsiloxane, magnesium trisilicate, potassium aluminum silicate and polydimethylsiloxane are some of the commercial anti-caking substances on the market.

The global anti-caking agents market is segmented into source, type of application and region. By source, the anti-caking agents market is segmented into natural and synthetic. Among these, the synthetic segment occupied the major share of the market in 2021 and is expected to maintain its dominance during the forecast period. The growth of the natural segment is attributed to the surge in demand for skiing and an increasing number of food industries. However, the natural segment is expected to grow at the highest CAGR in the future.

For a purchase request: https://www.alliedmarketresearch.com/purchase-enquiry/600

By type, it is classified into calcium compounds and sodium compounds, and others. The sodium compounds segment is expected to grow at the highest rate over the forecast period owing to the growing desire among the young population to enjoy health benefits.

According to the application, it is classified into dairy products, bakery, seasonings and condiments, and others. The bakery segment is expected to grow at the highest CAGR over the forecast period, owing to the consumption of bakery products such as cookies, muffins, pastries, and others. The sale of baking anti-caking agents is one of the fastest growing sales channels in the industry. Because they are readily available. In an effort to attract more customers, this platform offers a variety of discounts on purchases of baked goods.

In 2021, Europe accounted for 34.5% of the global anti-caking agents market share and is expected to maintain its dominance during the forecast period. The high demand for bakery food products has led to the use of food additives such as anti-caking agents in the region. Spain, Germany and France are expected to be the largest markets due to their higher feed production than other European countries. Driven by an increasing demand for higher quality meat products, the market for food additives in the region, especially anti-caking agents, is growing rapidly.

Connect to the analyst: https://www.alliedmarketresearch.com/connect-to-analyst/600

Under the influence of COVID-19, Food Anti-Caking Agents market trends are estimated to grow quite steadily. The market should have a smooth regulatory environment. End users are expected to accept food release agents to a moderate extent. There are slight trade/export restrictions post COVID-19 which may slightly hamper the growth of the Anti-Caking Agents Market. However, the regulatory framework supporting the food anti-caking agents market, wide consumer acceptance, favorable trade policies, new entrants, high investments, low competition with alternative products, and cost of ingredients are solidifying the food. Anti-caking agents are expected to drive the demand for baking agents in the future.

Key Players Analyzed for Global Anti-Caking Agents Industry are Evonik Industries AG (US), PPG Industries Inc. (US), Brenntag AG (Germany), Univar Solutions Inc. (US), Solvay SA (Belgium), Cabot Corporation (USA), Agropur Ingredients (USA), Huber Engineered Material, Kao Corp., IMAC Inc.

KEY FINDINGS OF THE STUDY

By source, the natural segment was the largest contributor to market revenue in 2021 and is expected to reach $1,041.8 million by 2031, growing at a CAGR of 6.0%.
Based on type, the calcium compounds segment was the largest contributor to market revenue in 2021, growing at a CAGR of 6.1%.
Based on applications, the dairy products segment dominated the global market in 2021 and is expected to remain dominant during the forecast period.
Regionally, Europe was the largest revenue contributor, accounting for $392.4 million in 2021, at a CAGR of 7.1%.

Access the full summary: https://www.alliedmarketresearch.com/anti-caking-agents-market

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
The Web: https://www.alliedmarketresearch.com
Follow us on: LinkedIn Twitter

About Us:
Allied Market Research (AMR) is a full-service market research and business consulting division of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global corporations as well as small and medium enterprises with unrivaled quality of “market research reports” and “Business Intelligence solutions”. AMR has a focused vision to provide business insights and advice to help its clients make strategic business decisions and achieve sustainable growth in their respective market area.

We maintain professional relationships with various companies which helps us to extract market data which helps us to generate accurate research data tables and confirm the utmost accuracy of our market predictions. Allied Market Research CEO Pawan Kumar helps inspire and encourage everyone associated with the company to maintain high quality data and help clients in every way possible to achieve success. All data presented in the reports we publish are drawn from primary interviews with senior managers of large companies in the relevant field. Our secondary data sourcing methodology includes extensive online and offline research and discussions with knowledgeable industry professionals and analysts.

This press release was published on openPR.

]]>
Royal Bank of Canada raised its price target on Mosaic (NYSE:MOS) to $60.00. https://imphos.org/royal-bank-of-canada-raised-its-price-target-on-mosaic-nysemos-to-60-00/ Fri, 11 Nov 2022 15:44:15 +0000 https://imphos.org/royal-bank-of-canada-raised-its-price-target-on-mosaic-nysemos-to-60-00/ According to Benzinga, equity research analysts at Royal Bank of Canada lowered their price target for Mosaic (NYSE: MOS) in a research report released Thursday. The report focused on the company’s shares. The previous price target of $65.00 has been revised to $60.00. In addition, the company assigned an “industry performance” rating to the company’s […]]]>

According to Benzinga, equity research analysts at Royal Bank of Canada lowered their price target for Mosaic (NYSE: MOS) in a research report released Thursday. The report focused on the company’s shares. The previous price target of $65.00 has been revised to $60.00. In addition, the company assigned an “industry performance” rating to the company’s common stock engaged in basic materials. The price target set for Royal Bank of Canada indicates upside potential of 20.89% when measured against the company’s current share price.

There have been published articles regarding the stock written by other research analysts. On October 12, a Wednesday, StockNews.com began covering Mosaic after it became a publicly traded company. Investors were encouraged to follow their recommendations and buy the shares. Citigroup raised its price target on Mosaic shares from $58.00 to $61.00 and assigned the stock a “buy” rating in a research note released Wednesday. Mizuho lowered its price target on Mosaic shares from $74.00 to $69.00 and gave the company a “buy” rating in a research note released Wednesday. JPMorgan Chase & Co. lowered its price target on Mosaic shares from $75.00 to $73.00 and gave the company an “overweight” rating in a report released Wednesday. Finally, on August 10, Barclays released a report that called the company “underweight” and lowered its price target on Mosaic shares from $59.00 to $52.00. The price target was previously $59.00. One equity research analyst suggested selling the stock, seven analysts suggested keeping it in their portfolio, and nine analysts suggested buying the stock. According to Bloomberg.com, the company receives an average recommendation of “Hold”, and the consensus price target for the company is currently $64.31.
When the market opened on Thursday, the price of one MOS share was $49.63 per share. The stock has a price-to-earnings ratio of 4.86 and its price-to-earnings-to-growth (PEG) ratio is 0.54. The beta value of the stock is 1.55. The company currently has a market cap of $17.97 billion. 1.30 is the value assigned to the current ratio, 0.65 is the value assigned to the quick ratio and 0.28 is the value assigned to the debt ratio. The company’s simple moving average over the past 50 days is $51.75; the simple moving average over the past 200 days is $53.65. Over the past year, Mosaic’s price fluctuated between $33.59 and $79.28, with an average price of $79.28.

On August 1, Mosaic announced that its board of directors had authorized the company to repurchase up to $2 billion of the company’s currently outstanding stock. This repurchase authorization will allow the company which operates in the basic materials industry to potentially repurchase up to 10.8% of its shares on the open market. When a company announces that it intends to repurchase its stock, it almost always indicates that management believes the stock is currently trading at a price lower than its true value.

Recently, institutional investors have rebalanced their investment portfolios by shifting the percentage of equity holdings. In the third quarter, Guardian Wealth Advisors LLC acquired an additional stake in Mosaic worth approximately $27,000. SJS Investment Consulting, Inc. acquired a new investment in Mosaic worth approximately $28,000 in the first three months of 2018. A new stake in Mosaic valued at approximately $33,000 was acquired by BerganKDV Wealth Management LLC during the first three months. months of 2018. During the first three months of 2018, High Net Worth Advisory Group LLC acquired a new position in Mosaic which was estimated to be worth approximately $33,000 at the time of purchase. Finally, in the first three months of this year, FourThought Financial LLC increased the number of Mosaic shares held by a factor of 5,000%. FourThought Financial LLC now owns 510 shares held by the basic materials company after acquiring an additional 500 shares in the last quarter. This brings the total number of shares she owns to a total of 510. There is a value of $34,000 associated with these shares. 82.24% of the company’s shares are held by hedge funds and other institutional investors.

The Mosaic Company, through its many subsidiaries, operates a business that is dedicated to the production and sale of phosphate concentrates and potassium nutrients throughout the North American continent and the rest of the world. The company is organized into three divisions: production of phosphate and potash, mosaic fertilizers and general fertilizers. It owns and operates mines that produce concentrated phosphate nutrients such as diammonium phosphate, monoammonium phosphate and ammonium phosphate products; and phosphate-based animal feed ingredients, primarily under the Biofos and Nexfos brands, as well as a K-Mag brand for a dual sulfate of potash and magnesia product. These products are sold primarily in North America. The United States of America accounts for the majority of sales of these products.

]]>
Analysis of triethyl phosphate market growth opportunities, https://imphos.org/analysis-of-triethyl-phosphate-market-growth-opportunities/ Tue, 08 Nov 2022 09:51:00 +0000 https://imphos.org/analysis-of-triethyl-phosphate-market-growth-opportunities/ Triethyl Phosphate, Major Triethyl Phosphate Market, Triethyl Phosphate Market, Triethyl Phosphate Market Share, Triethyl Phosphate Triethyl Phosphate Market Overview: Content of the Global Triethyl Phosphate report includes Triethyl Phosphate market size by value, drivers, trends, and challenges, by end-user, and growth rate during the forecast period, 2022- 2030. Historical figures are also provided. The study […]]]>

Triethyl Phosphate, Major Triethyl Phosphate Market, Triethyl Phosphate Market, Triethyl Phosphate Market Share, Triethyl Phosphate

Triethyl Phosphate Market Overview:

Content of the Global Triethyl Phosphate report includes Triethyl Phosphate market size by value, drivers, trends, and challenges, by end-user, and growth rate during the forecast period, 2022- 2030. Historical figures are also provided.

The study examines the current scenario of the global Triethyl Phosphate market and its market dynamics for the period 2022-2030. It covers a detailed overview of several market growth catalysts, restraints, and trends. The report assesses the size of the global Triethyl Phosphate market and studies the strategy patterns adopted by major international players. Additionally, the report estimates the market size in terms of revenue for the forecast period. All data figures such as percentage share breakdowns and breakdowns are determined using secondary sources and verified using primary sources. The report presents both the demand and supply sides of the market. It profiles and reviews the leading companies and other eminent ones operating in the market.

Get sample report @ https://reportsinsights.com/sample/445840

Leading competitors in the Global Triethyl Phosphate Market are:
Eastman, Lanxess, Ningguo Long Day Chemical, Jilin Yonglin, Hongzheng Chemical, Donghu Chemical

The report highlights key players and manufacturers and latest strategies including new product launches, partnerships, joint ventures, technology, regional and industry competition segmentation, profit and loss ratio and insights. of investment. An accurate assessment of effective manufacturing techniques, advertising techniques, market share size, growth rate, size, revenue, sales, and value chain analysis.

The main types of products covered are:
Industrial level
Superior category

The application coverage in the market is:
chemical catalyst
Fire retardant
Organic solvent
Pesticide intermediates
Others

The Triethyl Phosphate Market research report is a comprehensive and informative study on the current state of the industry of the global Triethyl Phosphate Market with a focus on the global industry. The report presents key statistics on the market status of the global Triethyl Phosphate market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

To get this report at a cost effective rate. : https://reportsinsights.com/discount/445840

Regional Triethyl Phosphate Market (Regional Production, Demand and Forecast by Country):-
North America (United States, Canada, Mexico)
South America (Brazil, Argentina, Ecuador, Chile)
Asia-Pacific (China, Japan, India, Korea)
Europe (Germany, UK, France, Italy)
Middle East Africa (Egypt, Turkey, Saudi Arabia, Iran) and more.

The research report studies the past, present and future performance of the global market. The report further analyzes the current competitive scenario, prevalent business models, and likely advances of offerings by prominent players in the coming years.

Important features of the report:
– Detailed analysis of the global triethyl phosphate market
– Fluctuating industry market dynamics
-Detailed market segmentation
– Historical, current and projected market size in terms of volume and value
– Recent industry trends and developments
– Competitive landscape of the global triethyl phosphate market
– Strategies of key players and product offerings
– Potential and niche segments/regions showing promising growth
– A neutral outlook on the performance of the global triethyl phosphate market

Order now@ https://reportsinsights.com/buynow/445840

Reasons for Buying Global Triethyl Phosphate Market Report:
1. Current and future prospects of the global Triethyl Phosphate market in both developed and emerging markets.
2. This report comprehensively segments the global Triethyl Phosphate market. It provides the closest approximations of revenue for the overall market and sub-segments across different verticals and regions.
3. The report helps stakeholders take the pulse of the Triethyl Phosphate market and provides them with insights on key market drivers, restraints, challenges, and opportunities.
4. Analysis of various market perspectives using Porter’s five forces analysis.
5. The segment expected to dominate the global triethyl phosphate market.
6. Regions expected to grow the fastest over the forecast period.
7. Identify the latest developments, global Triethyl Phosphate market shares, and strategies employed by major market players.

In addition, the market study confirms the major global players in the global triethyl phosphate market. Their key marketing strategies and advertising techniques have been highlighted to offer a clear understanding of the global Triethyl Phosphate market.

Access full report description, table of contents, table of figure, graph, etc. @ https://www.reportsinsights.com/industry-forecast/triethyl-phosphate-market-2026-445840

More Related Article:-

https://www.reportsinsights.com/industry-forecast/cancer-diagnostics-market-statistical-analysis-664813

https://www.reportsinsights.com/industry-forecast/filter-bags-market-statistical-analysis-664393

https://www.reportsinsights.com/industry-forecast/pet-diabetes-care-devices-market-statistical-analysis-663973

https://www.reportsinsights.com/industry-forecast/aluminum-casting-market-statistical-analysis-663553

https://www.reportsinsights.com/industry-forecast/feed-micronutrients-market-statistical-analysis-665050

Contact us:

(US) +1-214-272-0393

(UK) +44-20-8133-9198

Email: info@reportsinsights.com

Sales: sales@reportsinsights.com

About Us:

Reports Insights is the research industry leader providing contextual, data-centric research services to clients worldwide. The firm assists its clients in developing business policies and achieving sustainable growth in their respective market area. The industry provides consulting services, syndicated research reports, and custom research reports.

This press release was published on openPR.

]]>
VENTYX BIOSCIENCES, INC. Management report and analysis of the financial situation and operating results. (Form 10-Q) https://imphos.org/ventyx-biosciences-inc-management-report-and-analysis-of-the-financial-situation-and-operating-results-form-10-q/ Fri, 04 Nov 2022 21:32:07 +0000 https://imphos.org/ventyx-biosciences-inc-management-report-and-analysis-of-the-financial-situation-and-operating-results-form-10-q/ The following discussion and analysis of financial condition and results of operations should be read together with our condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and the related notes for the year ended December 31, 2021, which […]]]>
The following discussion and analysis of financial condition and results of
operations should be read together with our condensed consolidated financial
statements and the related notes included elsewhere in this Quarterly Report on
Form 10-Q, as well as our audited consolidated financial statements and the
related notes for the year ended December 31, 2021, which are included in our
Annual Report on Form 10-K filed with the Securities and Exchange Commission
("SEC") on March 23, 2022. In addition to historical financial information, the
following discussion and analysis and other parts of this Quarterly Report on
Form 10-Q contain forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, based upon current expectations that involve
risks and uncertainties. As a result of many factors, including those factors
set forth in Part II, Item 1A (Risk Factors) of this Quarterly Report on Form
10-Q, our actual results could differ materially from the results described in
or implied by the forward-looking statements contained in the following
discussion and analysis. Please also see the section titled "Special Note
Regarding Forward-Looking Statements."

Insight


We are a clinical-stage biopharmaceutical company developing a pipeline of novel
small molecule product candidates to address a range of inflammatory diseases
with significant unmet need. We leverage the substantial experience of our team
in immunology to identify important new targets and to develop differentiated
therapeutics against these targets. Our clinical product candidates address
therapeutic indications with substantial commercial opportunity for novel small
molecules. Our lead clinical product candidate, VTX958, is a selective
allosteric tyrosine kinase type 2 (TYK2) inhibitor. In August 2022, we announced
positive topline data from a Phase 1 single and multiple ascending dose trial of
VTX958 in healthy volunteers. We expect to initiate Phase 2 trials with VTX958
in the fourth quarter of 2022 for psoriasis, psoriatic arthritis and Crohn's
disease and continue to evaluate additional indications for clinical
development. In addition, we are developing VTX002, a sphingosine 1 phosphate
receptor (S1P1R) modulator in Phase 2 development for ulcerative colitis. We
initiated a Phase 2 trial with VTX002 in the fourth quarter of 2021 in patients
with moderate to severe ulcerative colitis. Our third product candidate,
VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3)
inflammasome inhibitor. In June 2022, we announced positive topline data from a
Phase 1 single and multiple ascending dose trial of VTX2735 in healthy
volunteers. We plan to initiate a Phase 2 trial for VTX2735 in
cryopyrin-associated periodic syndrome (CAPS) patients in the fourth quarter of
2022 and continue to evaluate additional indications for clinical development.
In addition to VTX2735, we nominated VTX3232, our lead CNS-penetrant NLRP3
inhibitor, as a clinical development candidate in the fourth quarter of 2021. We
plan to initiate a Phase 1 trial of VTX3232 in healthy volunteers in the first
quarter of 2023.

We were incorporated in November 2018. To date, we have focused primarily on
organizing and staffing our company, business planning, raising capital and
identifying our product candidates and conducting preclinical studies and
clinical trials. We have funded our operations primarily through debt and equity
financings. We do not have any products approved for sale and have not generated
any revenue from product sales.

We have incurred significant operating losses since our inception and expect to
continue to incur significant operating losses for the foreseeable future. Our
net losses were $30.5 million and $12.8 million for the three months ended
September 30, 2022 and 2021, respectively. Our net losses were $73.2 million and
$66.0 million for the nine months ended September 30, 2022 and 2021,
respectively. We had an accumulated deficit of $191.0 million as of September
30, 2022. We expect our expenses and operating losses will increase
substantially as we conduct our ongoing and planned clinical trials, continue
our research and development activities and conduct preclinical studies, and
seek regulatory approvals for our product candidates, as well as hire additional
personnel, protect our intellectual property and incur additional costs
associated with being a public company. Our net losses may fluctuate
significantly from quarter-to-quarter and year-to-year, depending on a variety
of factors, including the timing and scope of our preclinical studies and
clinical trials and our expenditures on other research and development
activities.

We do not expect to generate any revenue from product sales unless and until we
successfully complete clinical development and obtain regulatory approval for
one or more of our product candidates, which we expect will take a number of
years. If we obtain regulatory approval for any of our product candidates, we
expect to incur significant commercialization expenses related to product sales,
marketing, manufacturing and distribution. Accordingly, until such time as we
can generate substantial product revenues to support our cost structure, if
ever, we expect to finance our cash needs through equity offerings, debt
financings or other capital sources, including potentially collaborations,
licenses and other similar arrangements. However, we may be unable to raise
additional funds or enter into such other arrangements when needed on favorable
terms or at all. Our failure to raise capital or enter into such other
arrangements when needed could have a negative impact on our financial condition
and on our ability to pursue our business plans and strategies. If we are unable
to raise additional capital when needed, we could be forced to delay, limit,
reduce or terminate our product candidate development or future
commercialization efforts or grant rights to develop and market our product
candidates even if we would otherwise prefer to develop and market such product
candidates ourselves.

                                       20
--------------------------------------------------------------------------------

Private placement


On September 20, 2022, the Company issued and sold 5,350,000 shares of common
stock through a private placement. The common stock had a purchase price of
$33.00 per share for aggregate gross proceeds of approximately $176.6 million.
The Company received approximately $165.4 million in net proceeds after
deducting fees to the placement agents and offering expenses payable by the
Company.

Initial public offering


On October 25, 2021, we completed an initial public offering (IPO) of our common
stock in which we issued an aggregate of 10,893,554 shares of our common stock
(inclusive of 1,420,898 shares issued pursuant to the underwriters'
over-allotment option) at a price of $16.00 per share. The Company received net
proceeds of approximately $158.8 million, after deducting underwriting discounts
and commissions of $12.2 million and other offering expenses of $3.3 million.

In connection with the closing of the initial public offering, all 12.5 million
outstanding shares of Series A Convertible Preferred Stock (Series A Preferred
Stock), 18.8 million outstanding shares of Series A-1 Convertible Preferred
Stock (Series A-1 Preferred Stock) and 4.0 million shares of Series B
Convertible Preferred Stock (Series B Preferred Stock) converted into an
aggregate of 35.3 million shares of common stock.

Company update regarding conflict in Ukraine


We are currently conducting a Phase 2 trial of VTX002 in patients with
moderate-to-severe UC with enrollment originally projected to include patients
at clinical sites in Russia, Belarus and Ukraine. As a result of the military
conflict in Ukraine, we terminated plans to open clinical trial sites in Russia,
Belarus and Ukraine, which impacted our original clinical trial strategy. Our
operations at additional sites in the region could also be impacted in the
future. Additionally, if our relationships with any of our CROs is terminated,
we may be unable to enter into arrangements with alternative CROs on
commercially reasonable terms, or at all. Our ability to conduct clinical trials
in Russia, Belarus, Ukraine and elsewhere in the region may also become
restricted under applicable sanctions laws. All of the foregoing creates
uncertainty around our ability to project the timing for enrollment of our Phase
2 trial for VTX002 and may lead to increased clinical trial costs as we seek to
open additional clinical sites to offset potential impact to our projected
enrollment in Russia, Belarus and Ukraine, which could materially harm our
business.

We have no way to predict the progress or outcome of the situation, as the
conflict and government reactions are rapidly developing and beyond our control.
Prolonged unrest, military activities, or broad-based sanctions, should they be
implemented, could have a material adverse effect on our operations and business
outlook.

COVID-19

The global COVID-19 pandemic and the related variants continue to rapidly
evolve. The extent of the impact of the COVID-19 pandemic on our business,
operations and clinical development timelines and plans remains uncertain, and
will depend on certain developments, including the duration and spread of the
outbreak and its impact on our operations and those of our CROs, third-party
manufacturers and other third parties with whom we do business, as well as its
potential impact on regulatory authorities and our ability to attract and retain
key scientific and management personnel.

We are conducting business as usual, with necessary or advisable modifications,
and have modified our business practices, including but not limited to,
modifying employee travel and allowing office employees to work remotely. We
will continue to actively monitor the rapidly evolving situation related to
COVID-19. We may take further actions that alter our operations, including those
that may be required by federal, state or local authorities, or that we
determine are in the best interests of our employees and other third parties
with whom we do business.


                                       21
--------------------------------------------------------------------------------

Asset purchases

As part of our Series A and Series A-1 Convertible Preferred Share financing, in February 2021we acquired all of the outstanding shares and convertible debt securities of Oppilan Pharma, Ltd. (Oppilan) and Zomagen Biosciences, Ltd. (Zomagen) (asset acquisitions). Certain Oppilan and Zomagen investors are also investors in the Company and are considered related parties. The details of the asset acquisitions are as follows:

Pursuant to the terms of the Share Purchase Agreement (the Oppilan Purchase
Agreement), upon closing, we issued to the shareholders of Oppilan 360,854
shares of our common stock valued at $3.06 per share, 4,049,143 shares of our
Series A-1 Convertible Preferred Stock valued at $3.06 per share and options to
purchase 75,955 shares of our common stock valued at a weighted average fair
value of $1.86 per share in exchange for all of the outstanding equity interests
of Oppilan. Oppilan's lead candidate, VTX002, is a modulator of the S1P1
receptor that has a unique pharmacokinetic and pharmacodynamic profile. A Phase
2 clinical trial of VTX002 for the treatment of moderate-to-severe ulcerative
colitis is currently ongoing.

Pursuant to the terms of the Share Purchase Agreement (the Zomagen Purchase
Agreement), upon closing, we issued to the shareholders of Zomagen 457,944
shares of our common stock valued at $3.06 per share, 2,003,768 shares of our
Series A-1 Convertible Preferred Stock valued at $3.06 per share and options to
purchase 30,483 shares of our common stock valued at a weighted average fair
value of $2.87 per share in exchange for all of the outstanding equity interests
of Zomagen. Zomagen's lead candidate, VTX2735, is a peripheral NLRP3 inhibitor
for which we completed a Phase 1 trial in the second quarter of 2022. We plan to
initiate a Phase 2 clinical trial of VTX2735 in cryopyrin-associated periodic
syndrome ("CAPS") patients in the fourth quarter of 2022 and continue to
evaluate additional indications for clinical development.

The fair value of total cost of the Asset Acquisitions was $14.0 million and
$7.8 million for Oppilan and Zomagen, respectively. The excess of the cost of
acquisition over net assets acquired was $12.8 million and $8.9 million for
Oppilan and Zomagen, respectively. We determined that there is no alternative
future use of the in-process research and development (IPR&D) assets acquired
from either acquisition. In accordance with the accounting for Asset
Acquisitions, the excess of the cost of acquisition over net assets acquired was
expensed as IPR&D at the respective acquisition date. For the year ended
December 31, 2021, we recorded the excess IPR&D costs of $21.7 million in
research and development costs within our unaudited condensed consolidated
statements of operations and comprehensive loss.

Overview of financial operations

Revenue


We have not generated any revenue since our inception and do not expect to
generate any revenue from the sale of products for the foreseeable future. We
may also generate revenues in the future from payments or royalties associated
with potential partnering or collaboration agreements, but have no plans to
enter into such arrangements at this time.

Research and development costs


Research and development expense consists of expenses incurred while performing
research and development activities to discover and develop our product
candidates. Research and development costs include salaries, payroll taxes,
employee benefits, and stock-based compensation charges for those individuals
involved in our ongoing research and development efforts; as well as fees paid
to consultants and third party research organizations, and the costs of
laboratory supplies and development compound materials. Costs incurred in our
research and development efforts are expensed as incurred.


                                       22
--------------------------------------------------------------------------------

We typically use our employee, consultant and infrastructure resources across
our research and development programs. We track outsourced development costs by
product candidate or development program, but we do not allocate personnel
costs, other internal costs or external consultant costs to specific product
candidates or development programs. These costs are included in unallocated
research and development expenses. The following table summarizes research and
development expenses by product candidate or development program (in thousands):

                                                   Three Months Ended           Nine Months Ended
                                                     September 30,                September 30,
                                                   2022          2021           2022          2021
VTX958                                          $    8,438     $   3,536     $   18,238     $   8,646
VTX002                                               7,956         3,945         15,690         6,961
VTX2735                                              3,050           776          6,862         1,988
Unallocated research and development expenses        6,024         2,288         16,763        27,062
Total research and development expenses         $   25,468     $  10,545    

$57,553 $44,657




We did not separately categorize costs related to VTX3232 in the table above due
to the early-stage development status of the drug product candidate during the
periods presented.

Substantially all of our research and development expenses to date have been
incurred in connection with the discovery and development of our product
candidates. We expect our research and development expenses to increase
significantly for the foreseeable future as we advance an increased number of
our product candidates through clinical development, including the conduct of
our ongoing and planned clinical trials. The process of conducting clinical
trials necessary to obtain regulatory approval is costly and time consuming. The
successful development of product candidates is highly uncertain and subject to
numerous risks and uncertainties. Accordingly, at this time, we cannot
reasonably estimate the nature, timing or costs required to complete the
remaining development of any product candidates and to obtain regulatory
approval for one or more of these product candidates.

Clinical trial costs can vary significantly over the life of a project due to, but not limited to, the following:

trial costs per patient;

the number of sites included in clinical trials;

the countries in which the clinical trials are conducted;

the length of time required to enroll eligible patients;

the number of patients who participate in clinical trials and the dropout or discontinuation rates of such patients;

the number of doses patients receive;

the cost of comparative agents used in clinical trials;

potential additional safety monitoring or other studies requested by regulatory agencies;

the duration of patient follow-up; and

the efficacy and safety profile of the product candidate.

We do not expect any of our product candidates to be commercially available in the next few years, if ever.

General and administrative expenses


General and administrative expenses are related to finance, human resources,
legal and patent costs and other administrative activities. These expenses
consist primarily of personnel costs, including stock-based compensation
expenses, outside services, legal expenses, management fees and other general
and administrative costs.

We expect that our general and administrative expenses will increase for the
foreseeable future as we expand operations, increase our headcount to support
our continued research and development activities and operate as a public
reporting company (including increased fees for outside consultants, lawyers and
accountants, as well as increased directors' and officers' liability insurance
premiums). We have also incurred, and expect to continue to incur, increased
costs to comply with stock exchange listing and SEC

                                       23
--------------------------------------------------------------------------------

requirements, corporate governance, internal controls, investor relations and
disclosure and similar requirements applicable to public companies.
Additionally, if and when we believe that a regulatory approval of a product
candidate appears likely, we expect to incur significant increases in our
general and administrative expenses related to the sales and marketing of any
approved product candidate.

Results of Operations

The presentation of our condensed consolidated financial statements for the
three and nine months ended September 30, 2021, reflect the financial results of
Ventyx Biosciences, Inc., and the financial results of our two acquired
subsidiaries, Oppilan and Zomagen, from the acquisition date to September 30,
2021, on a consolidated basis.

Comparison of the three months ended September 30, 2022 at three months ended
September 30, 2021

The following table summarizes our condensed consolidated results of operations for the three months ended September 30, 2022 and 2021:

                                                    Three Months Ended
                                                      September 30,
                                                   2022           2021           Change
                                                             (in thousands)
Operating expenses:
Research and development (includes related
party amounts of
  $220 and $287, respectively)                  $   25,468     $    10,545     $   14,923
General and administrative                           5,952           2,242          3,710
Total operating expenses                            31,420          12,787         18,633
Loss from operations                               (31,420 )       (12,787 )      (18,633 )
Other income:
Other income                                          (958 )           (13 )         (945 )
Total other income                                    (958 )           (13 )         (945 )
Net loss                                           (30,462 )       (12,774 )      (17,688 )
Unrealized gain on marketable securities                17               6             11
Foreign currency translation                           (38 )            23            (61 )
Comprehensive loss                              $  (30,483 )   $   (12,745 )   $  (17,738 )


Research and development costs


Research and development expenses were $25.4 million and $10.5 million for the
three months ended September 30, 2022 and 2021, respectively. For the three
months ended September 30, 2022 and 2021, most research and development expenses
have been related to the development of VTX958, VTX002 and VTX2735.

The increase of $14.9 million was due to increases in costs associated with the
Phase 1 and Phase 2 trials for VTX958 of approximately $5.2 million, stock-based
compensation expense of approximately $1.4 million, compensation related
expenses of approximately $1.2 million, consultant fees of approximately $0.4
million and expenses from the operations of Oppilan and Zomagen. The increased
expenses from the operations of Oppilan were attributable to an increase in
costs associated with the Phase 2 trial for VTX002 of approximately $4.0
million. The increased expenses from the operations of Zomagen were primarily
attributable to an increase in costs associated with the Phase 1 trial for
VTX2735 and IND enabling studies for VTX3232 of approximately $2.7 million.

General and administrative costs


General and administrative expenses were $5.9 million and $2.2 million for the
three months ended September 30, 2022 and 2021, respectively. The increase of
$3.7 million was primarily due to increased personnel costs, including
stock-based compensation of approximately $1.8 million, professional service
fees of approximately $0.7 million and compensation related expenses of
approximately $0.4 million, insurance costs of approximately $0.5 million and
other general and administrative expenses of approximately $0.3 million,
including dues and subscriptions, office supplies and equipment and facility
related costs.

Other Income

Other income was $1.0 million and $0 for the three months ended September 30,
2022 and 2021, respectively. During the three months ended September 30, 2022,
the other income recognized was associated with interest earned on
available-for-sale marketable securities.

                                       24
--------------------------------------------------------------------------------

Comparison of the nine months ended September 30, 2022 nine months ended
September 30, 2021

The following table summarizes our condensed consolidated results of operations for the nine months ended September 30, 2022 and 2021:

                                                    Nine Months Ended
                                                      September 30,
                                                   2022           2021           Change
                                                             (in thousands)
Operating expenses:
Research and development (includes related
party amounts of
  $653 and $839, respectively)                  $   57,553     $    44,657     $   12,896
General and administrative (includes related
party amounts of
  $0 and $116, respectively)                        17,012           4,664         12,348
Total operating expenses                            74,565          49,321         25,244
Loss from operations                               (74,565 )       (49,321 )      (25,244 )
Other (income) expense:
Other (income) expense                              (1,353 )            31         (1,384 )
Interest expense - related party                         -              99            (99 )
Change in fair value of notes and derivative
- related party                                          -          11,051        (11,051 )
Change in fair value of Series A tranche
liability                                                -           5,476         (5,476 )
Total other (income) expense                        (1,353 )        16,657        (18,010 )
Net loss                                           (73,212 )       (65,978 )       (7,234 )
Deemed dividend                                          -          (1,552 )        1,552
Net loss attributable to common shareholders    $  (73,212 )   $   (67,530 )   $   (5,682 )
Net loss                                        $  (73,212 )   $   (65,978 )   $   (7,234 )
Unrealized gain (loss) on marketable
securities                                          (1,204 )             6         (1,210 )
Foreign currency translation                           (50 )            11            (61 )
Comprehensive loss                              $  (74,466 )   $   (65,961 )   $   (8,505 )


Research and development costs


Research and development expenses were $57.6 million and $44.7 million for the
nine months ended September 30, 2022 and 2021, respectively. For the nine months
ended September 30, 2022, most research and development expenses have been
related to the development of VTX958, VTX002 and VTX2735.

For the nine months ended September 30, 2022 as compared to the nine months
ended September 30, 2021, there was a net increase in research and development
expenses of approximately $12.9 million. This increase was comprised of
increases in costs between periods associated with the Phase 1 and Phase 2
trials for VTX958 of approximately $9.6 million, stock-based compensation
expense of approximately $4.0 million, compensation related expenses of
approximately $3.5 million, consulting fees of $0.7 million, drug candidate
discovery costs of approximately $0.5 million and expenses from the operations
of Oppilan and Zomagen. The increased expenses from the operations of Oppilan
were attributable to an increase in costs associated with the Phase 2 trial for
VTX002 of $8.7 million. The increased expenses from the operations of Zomagen
were primarily attributable to an increase in costs associated with the Phase 1
trial for VTX2735 and IND enabling studies for VTX3232 of approximately $6.5
million and drug candidate discovery costs of approximately $1.2 million.

These increases between the nine months ended September 30, 2022 and 2021 were
offset by a $21.8 million non-cash IPR&D expense associated with the
acquisitions of Oppilan and Zomagen (as there was no alternative future use of
the IPR&D assets acquired) which was recognized during the nine months ended
September 30, 2021.

General and administrative costs


General and administrative expenses were $17.0 million and $4.7 million for the
nine months ended September 30, 2022 and 2021, respectively. The increase of
$12.3 million was primarily due to increased personnel costs, including
stock-based compensation of approximately $6.4 million, compensation related
expenses of approximately $1.8 million and professional service fees of
approximately $1.8 million, insurance costs of approximately $1.6 million and
other general and administrative expenses of approximately $0.7 million,
including dues and subscriptions, investor relations costs and facility related
costs.

                                       25
--------------------------------------------------------------------------------

Other (income) Expenses


Other income was $1.4 million for the nine months ended September 30, 2022 and
other expense was $16.7 million for the nine months ended September 30, 2021.
During the nine months ended September 30, 2022, the other income recognized was
associated with interest earned on available-for-sale marketable securities of
approximately $1.5 million, slightly offset by franchise tax costs of
approximately $0.2 million.

During the first quarter of 2021, in conjunction with the acquisitions of
Oppilan and Zomagen, the convertible promissory notes (Convertible Notes) and
Simple Agreements for Future Equity (SAFEs or Convertible SAFE Notes) converted
into Series A and Series A-1 Preferred Stock, eliminating the fair value
accounting associated with the Convertible Notes, SAFEs and the associated
derivative liability. During the nine months ended September 30, 2021, the
Company recognized a change in the fair value of the Series A tranche liability
of approximately $5.5 million.

We issued the Convertible Notes in 2019 and 2020 which included a change of
control feature for which we recorded a liability measured at fair value. We
estimated the fair value of our change of control feature using a combination of
probability analysis and Monte Carlo simulation methodology. Until their
conversion into Series A-1 Preferred Stock in February 2021, we adjusted the
carrying value of our change in control feature to its estimated fair value at
each reporting date, with the increases in fair value of the change of control
feature recorded in our condensed consolidated statements of operations and
comprehensive loss.

We issued SAFEs in 2019 and 2020 which we accounted for at fair value. We
estimated the fair value of our SAFEs using a combination of probability
analysis and Monte Carlo simulation methodology. Until their conversion into
Series A-1 Preferred Stock in February 2021, we adjusted the carrying value of
our SAFEs to their estimated fair value at each reporting date, with the
increases in fair value of the SAFEs recorded in our condensed consolidated
statements of operations and comprehensive loss.

On February 26, 2021, we issued 6,283,401 shares of our Series A Preferred Stock
for gross proceeds of $57.3 million at the original issue price of $9.12 per
share. The Series A purchase agreement allowed the original investors to
purchase an additional 6,250,504 shares of Series A Convertible Preferred Shares
(the Additional Shares) on the same terms and conditions as the original
issuance at the original issuance price of $9.12 per share (the Second Closing
or Tranche Liability). In addition, we were obligated to issue 507,133 shares of
common stock to a Series A investor if such investor participated in the second
tranche. We concluded that these rights or obligations of the investors to
participate in the second tranche of the Series A Preferred Stock met the
definition of a freestanding instrument that was required to be recorded as a
liability at fair value (Series A tranche liability). Given the common shares
were linked to the second tranche, they were also considered a component of the
Tranche Liability. On June 10, 2021, the investors purchased an additional
6,250,504 shares of our Series A convertible preferred stock, on the same terms
and conditions as the original issuance for gross proceeds of $57.0 million in a
second closing.

Until the conversion of the Series A tranche liability into Series A Preferred
Stock on June 10, 2021, we adjusted the carrying value of our Series A tranche
liability to its estimated fair value at each reporting date. We estimated the
fair value of the Series A tranche liability using a combination of probability
analysis and Monte Carlo simulation methodology. The increases in fair value of
the Series A tranche liability were recorded as an increase in fair value of our
Series A tranche liability in our condensed consolidated statements of
operations and comprehensive loss.

In the nine months ended September 30, 2021the Company recognized a change in fair value of the change of control feature and SAFEs of approximately $11.1 million and a change in the fair value of the Series A tranche liability of approximately $5.5 million.

Cash and capital resources

Sources of liquidity and capital resources


From inception through September 30, 2022, we have funded our operations
primarily through the issuance of $164.2 million of convertible preferred stock,
net of offering costs, to outside investors and related parties and $10.3
million in aggregate principal amount of convertible notes and SAFEs issued to
related parties. In October 2021, we received net proceeds of approximately
$158.8 million, after deducting underwriting discounts and commissions and
offering expenses payable by us, from the sale of our shares of common stock in
the IPO. Additionally, in September 2022 through the closing of our private
placement, we received net proceeds of approximately $165.4 million after
deducting transaction-related expenses. As of September 30, 2022, we had cash,
cash equivalents and marketable securities of $412.4 million.

We have not entered into any off-balance sheet arrangements, as defined in the rules and regulations of the SECOND.

                                       26
--------------------------------------------------------------------------------

Future funding needs


To date, we have generated no revenue and do not expect to generate revenue
unless and until we obtain regulatory approval of and commercialize any of our
product candidates and we do not know when, or if, this will occur. In addition,
we expect our expenses to significantly increase in connection with our ongoing
development activities, particularly as we continue the research, development
and clinical trials of, and seek regulatory approval for, our product
candidates. Moreover, we expect to incur additional costs associated with
operating as a public company. In addition, subject to obtaining regulatory
approval of our product candidates, we expect to incur significant
commercialization expenses for product sales, marketing, manufacturing and
distribution. We anticipate that we will need substantial additional funding in
connection with our continuing operations. We expect that our expenses will
increase substantially if and as we:

continue research and development, including preclinical and clinical development of our existing product candidates;

seek regulatory approval for our product candidates;

seek to discover and develop additional product candidates;

establish a commercialization infrastructure and scale up our manufacturing and
distribution capabilities to commercialize any of our product candidates for
which we may obtain regulatory approval;

seek to comply with regulatory standards and laws;

maintain, operate and develop our intellectual property portfolio;

hire clinical, manufacturing, scientific and other personnel to support our product candidates;

incur expenses related to future development and commercialization efforts;

add staff, financial and management information systems, and personnel; and

incur additional legal, accounting and other expenses in connection with operating as a public company.


Based upon our current operating plan, we expect that our cash, cash equivalents
and marketable securities as of September 30, 2022, will enable us to fund our
operating expenses and capital expenditures requirements into 2025. We have
based this estimate on assumptions that may prove to be wrong, and we may use
our available capital resources sooner than we currently expect.

We enter into contracts in the normal course of business with various
third-party consultants, contract research organizations (CRO) and contract
manufacturing organizations (CMO) for preclinical research, clinical trials and
manufacturing activities. These contracts generally provide for termination upon
notice. Payments due upon cancellation consist of cancellation fees and payments
for services provided or expenses incurred, including non-cancellable
obligations of our service providers, up to the date of cancellation. Actual
expenses associated with these arrangements may be higher or lower than
anticipated due to various factors, including progress of our development
candidates, enrollment in ongoing clinical trials, which may be competitive and
challenging and results from our ongoing and planned clinical trials.

Material short-term liquidity needs of $0.5 million relate to future minimum
lease payments. Material long-term liquidity needs pertaining to our operating
leases is approximately $1.4 million with our last minimum lease payment due in
June 2026. Currently, we have no short-term or long-term purchase commitments.

Our capital expenditures to date have been negligible and we do not expect to incur any significant capital expenditure costs in the short or long term.

The success of the development of any product candidate is highly uncertain. Due to the many risks and uncertainties associated with the development and commercialization of our product candidates, if approved, we are unable to estimate the amounts of increased capital and operating expenses. associated with the completion of the development of our product candidates.

                                       27
--------------------------------------------------------------------------------

Our future capital requirements will depend on many factors, including:

the timing and costs involved in preclinical and clinical development and obtaining any regulatory approval for our product candidates;

the costs of manufacturing, distributing and processing our product candidates;

the number and characteristics of any other product candidates we develop or acquire;

the degree and rate of market acceptance of any approved product;

the emergence, approval, availability, perceived benefits, relative cost, relative safety and relative effectiveness of other products or treatments;

expenditures necessary to attract and retain qualified personnel;

the costs associated with being a public company;

costs related to the preparation, filing, prosecution, maintenance, defense and enforcement of intellectual property claims, including litigation costs and the outcome of such litigation;

the timing, receipt and amount of sales or royalties on any approved product; and

any product liability or other legal claims related to our product candidates.


Until such time, if ever, as we can generate substantial product revenues, we
expect to finance our cash needs through a combination of equity, equity-linked
and debt financings, collaborations, strategic alliances and/or licensing
arrangements. We do not have any committed external source of funds. To the
extent that we raise additional capital through the sale of equity or
convertible debt securities, the ownership interest of our stockholders will be
diluted, and the terms of these securities may include liquidation or other
preferences that adversely affect the rights of common stockholders. Debt
financing, if available, may involve agreements that include covenants limiting
or restricting our ability to take specific actions, such as incurring
additional debt, making capital expenditures or declaring dividends. If we raise
additional funds through collaborations, strategic alliances or licensing
arrangements with pharmaceutical partners, we may have to relinquish valuable
rights to our technologies, future revenue streams, research programs or product
candidates, or grant licenses on terms that may not be favorable to us. If we
are unable to raise additional funds through equity or debt financings when
needed, we may be required to delay, limit, reduce or terminate our product
development or future commercialization efforts or grant rights to develop and
market our product candidates that we would otherwise prefer to develop and
market ourselves.

Cash flow


We have incurred net losses and negative cash flows from operations since our
inception and anticipate we will continue to incur net losses for the
foreseeable future. As of September 30, 2022, we had cash, cash equivalents and
marketable securities of $412.4 million.

The following table sets forth a summary of the net cash flow activity for each
of the periods indicated:

                                     Nine Months Ended
                                       September 30,
                                    2022          2021
                                      (in thousands)
Net cash provided by (used in):
Operating activities              $ (51,507 )   $ (23,963 )
Investing activities              $  65,909     $ (71,275 )
Financing activities              $ 178,127     $ 163,969



Operating Activities

Net cash used in operating activities was $51.5 million for the nine months
ended September 30, 2022 and was primarily due to our net loss of $73.2 million
offset by $11.5 million for noncash items and a net increase of $10.2 million in
operating assets and liabilities. The noncash items included approximately $11.7
million for stock-based compensation expense and approximately $0.3

                                       28
--------------------------------------------------------------------------------

million for the amortization of operating right-of-use assets and depreciation
expense, slightly offset by approximately $0.5 million for the net
accretion/amortization of investments in available-for-sale marketable
securities. The $10.2 million change in operating assets and liabilities was
primarily attributable to an increase in accrued expenses and accounts payable
of approximately $11.9 million, offset by an increase in prepaid expenses and
other assets of approximately $1.5 million.

Net cash used in operating activities was $24.0 million for the nine months
ended September 30, 2021 and was primarily due to our net loss of $66.0 million
offset by $39.8 million for noncash items and a net increase in operating assets
and liabilities of approximately $2.3 million. The noncash items included $21.8
million for acquired IPR&D expenses, $16.6 million due to the change in the fair
value of related party notes, the associated derivative, and the Series A
tranche liability and $1.3 million for stock-based compensation expense. The
$2.3 million change in operating assets and liabilities was primarily
attributable to increases in accrued expenses and accounts payable of $5.9
million, offset by an increase in prepaid expenses and other assets of $3.6
million.

Investing activities


Net cash provided by investing activities was $65.9 million for the nine months
ended September 30, 2022 and was related to $208.6 million in proceeds from
maturities of available-for-sale marketable securities, offset by the purchase
of $142.5 million of investments in available-for-sale marketable securities.
Net cash used in investing activities was $71.3 million for the nine months
ended September 30, 2021 related to the purchase of $73.0 million of investments
in available-for-sale marketable securities, partially offset by $1.9 million of
net cash assumed in connection with the acquisitions of Oppilan and Zomagen.

Fundraising activities


Net cash provided by financing activities was $178.1 million for the nine months
ended September 30, 2022 and was attributable to approximately $176.5 million in
net proceeds from the issuance of common stock from the private placement, $1.5
million in proceeds from the exercise of stock options, and $0.1 million in
proceeds from the issuance of common stock under the 2021 Employee Stock
Purchase Plan (ESPP). Net cash provided by financing activities was $164.0
million for the nine months ended September 30, 2021 and was primarily
attributable to $164.2 million in proceeds from the issuance of our Series A and
Series B Preferred Stock net of offering costs and $0.5 million in net proceeds
from the issuance of SAFEs, partially offset by $0.7 million of cash paid for
deferred offering costs.

Significant Accounting Policies and Estimates


Our management's discussion and analysis of our financial condition and results
of operations are based on our condensed consolidated financial statements,
which have been prepared in accordance with U.S. generally accepted accounting
principles (GAAP). The preparation of these condensed consolidated financial
statements requires us to make estimates and judgments that affect the reported
amounts of assets, liabilities, and expenses, and the disclosure of contingent
assets and liabilities in our unaudited condensed consolidated financial
statements. On an ongoing basis, we evaluate our estimates and judgments,
including those related to prepaid and accrued clinical trial and research and
development costs, available-for-sale marketable securities, the measurement of
operating lease right-of-use assets and operating lease liabilities and the
measurement of the fair value of stock-based awards. We base our estimates on
historical experience, known trends and events, and various other factors that
are believed to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and
liabilities that are not readily apparent from other sources. Actual results may
differ from these estimates under different assumptions or conditions.

During the three and nine months ended September 30, 2022, there have been no
material changes to our critical accounting policies and estimates from those
described in "Management's Discussion and Analysis of Financial Condition and
Results of Operations," included in our Annual Report on Form 10-K filed with
the SEC on March 23, 2022.

Other Company Information

Jumpstart Our Business Startups Act (“JOBS Act”)


We are an "emerging growth company," as defined in the JOBS Act, and we may take
advantage of reduced reporting requirements that are otherwise applicable to
public companies. We have elected to take advantage of the extended transition
period for complying with new or revised accounting standards; and as a result
of this election, our financial statements may not be comparable to companies
that comply with public company effective dates. The JOBS Act also exempts us
from having to provide an auditor attestation of internal control over financial
reporting under Sarbanes-Oxley Act Section 404(b).

We will remain an "emerging growth company" until the earliest to occur of (1)
the last day of the fiscal year in which our annual gross revenue is $1.235
billion or more, (2) the last day of 2026, (3) the date that we become a "large
accelerated filer" as defined in

                                       29
--------------------------------------------------------------------------------

Rule 12b-2 under the Exchange Act, which would occur if the market value of our
common stock that is held by non-affiliates exceeds $700.0 million as of the
last business day of our most recently completed second fiscal quarter and (4)
the date on which we have issued more than $1.0 billion in non-convertible debt
securities during any three-year period.

We are also a "smaller reporting company" because the market value of our stock
held by non-affiliates plus the aggregate amount of gross proceeds to us as a
result of our initial public offering is less than $700 million as of June 30,
2021, and our annual revenue was less than $100 million during the fiscal year
ended December 31, 2021. We may continue to be a smaller reporting company in
any given year if either (i) the market value of our stock held by
non-affiliates is less than $250 million as of June 30 in the most recently
completed fiscal year or (ii) our annual revenue is less than $100 million
during the most recently completed fiscal year and the market value of our stock
held by non-affiliates is less than $700 million as of June 30 in the most
recently completed fiscal year. If we are a smaller reporting company at the
time we cease to be an emerging growth company, we may continue to rely on
exemptions from certain disclosure requirements that are available to smaller
reporting companies. Specifically, as a smaller reporting company we may choose
to present only the two most recent fiscal years of audited consolidated
financial statements in our Annual Report on Form 10-K.

Recent accounting pronouncements


A description of recent accounting pronouncements that may potentially impact
our financial positions, results of operations or cash flows is disclosed in
Note 2 of our condensed consolidated financial statements included elsewhere in
this Quarterly Report on Form 10-Q.

© Edgar Online, source Previews

]]>
Raman-based single-cell tool developed for efficient extraction of living functional microbes from nature https://imphos.org/raman-based-single-cell-tool-developed-for-efficient-extraction-of-living-functional-microbes-from-nature/ Wed, 02 Nov 2022 08:42:00 +0000 https://imphos.org/raman-based-single-cell-tool-developed-for-efficient-extraction-of-living-functional-microbes-from-nature/ Currently, the best way for scientists to isolate a specific microbe with a particular metabolic function from an environment is to take a sample of cells, culture them, and then screen them for the desired cell functions. This method has several limitations. First, the scientists failed to identify most cells in nature, limiting the results […]]]>

Currently, the best way for scientists to isolate a specific microbe with a particular metabolic function from an environment is to take a sample of cells, culture them, and then screen them for the desired cell functions.

This method has several limitations. First, the scientists failed to identify most cells in nature, limiting the results to previously cultured cells. Second, the way cells behave in a test tube is not necessarily how they behave in nature or in situ. This can make it difficult to identify the right cell with the right metabolic functions.

Researchers from the Qingdao Institute of Bioenergy and Bioprocess Technology (QIBEBT) of the Chinese Academy of Sciences (CAS) have proposed a new technique called single-cell Raman-activated sorting and culturing, or scRACS-Culture, to find and harvest cells from the environment by first screening the cells and then culturing them.

The study was published in ISME Communications on October 30.

“Mining based on the function of nature’s microbes has traditionally used a ‘culture first, screen later’ strategy, which has several limitations,” said JING Xiaoyan, the paper’s first author and lead engineer. of the QIBEBT Single-Cell Center. “Using phosphate-solubilizing microbes as a model, we introduced a ‘screening-first’ strategy called Raman-enabled single-cell sorting and culturing.”

Using a new instrument called RACS-Seq, researchers demonstrated the feasibility of scRACS-Culture by extracting microbes for in situ solubilization activity of organic phosphates from an urban wastewater treatment plant. This shows a real use case for this technology, as these organic phosphate-solubilizing strains are highly sought after resources, as they can combat pollution of water bodies and soils, promote nutrient uptake of crops, improve fertilizer efficiency and reduce use. chemical fertilizers.

The researchers used the scRACS-Culture method to extract these cells directly from a wastewater sample, examining their metabolic rate when only organic phosphate substrates are available. They pointed out that such a culture-independent, “screen-first” strategy is advantageous in that it can screen all cells in a microbiome, instead of just those cells that can be cultured.

Additionally, this strategy can assess the in situ function of the cell, which is generally more relevant than the function of a pure culture in a test tube. It is also applicable to a wide variety of valuable metabolic functions of cells. “Because this technique can measure a wide range of metabolic phenotypes without a fluorescence probe, it should greatly expand the use of function-driven single-cell technologies in microbiome science and industries,” said co-first author GONG Yanhai, research assistant at the Single-Cell Center of QIBEBT.

To improve the success rate of scRACS-Culture, they envision a strategy that releases the target cell’s nutrient needs through the metabolic reconstruction of its single-cell genome. The knowledge can then be used to optimize the culture medium to transform these individual cells yet to be grown into cultures of valuable live bacteria, for animal and plant health and for environmental remediation.

Looking ahead, the team plans to further increase the scale and throughput of the technology, to efficiently extract ‘probiotics’ from a wide range of ecosystems, according to Professor XU Jian of QIBEBT’s Single Cell Center, who led the study.

/Public release. This material from the original organization/authors may be ad hoc in nature, edited for clarity, style and length. The views and opinions expressed are those of the author or authors.View Full here.

]]>
UF study shows sewage plant by-product is good for seagrass https://imphos.org/uf-study-shows-sewage-plant-by-product-is-good-for-seagrass/ Sun, 30 Oct 2022 21:17:40 +0000 https://imphos.org/uf-study-shows-sewage-plant-by-product-is-good-for-seagrass/ by Kirsten Romaguera, UF/IFAS Seagrasses are vital to the marine ecosystem, where they provide food, habitat, shelter and other services to humans and aquatic organisms. But while the success of seagrass beds is threatened by a few factors, including human activities like boating, a crystallized version of human waste could be the answer to revitalizing […]]]>

by Kirsten Romaguera, UF/IFAS

Seagrasses are vital to the marine ecosystem, where they provide food, habitat, shelter and other services to humans and aquatic organisms. But while the success of seagrass beds is threatened by a few factors, including human activities like boating, a crystallized version of human waste could be the answer to revitalizing these marine habitats.

Urine, it turns out, includes two key ingredients in plant fertilizers: phosphorus and nitrogen. Even better, wastewater treatment facilities are already treating this abundant resource and creating byproducts that would otherwise be sent to landfill.
In its crystallized form, this byproduct is called struvite, the material applied to seagrass beds in a recent study by scientists at the University of Florida.

“Struvite occurs during the wastewater treatment process because magnesium, ammonia and phosphate are all readily available to form the crystalline byproduct,” said Conor MacDonnell, who conducted the study as PhD student. student in the Department of Soil, Water and Ecosystem Sciences at UF/IFAS. “The result is a relatively insoluble and durable compound that is found in wastewater treatment plants.”

This relative insolubility led MacDonnell – who graduated in 2021 and now works as a UF postdoctoral associate studying seagrass restoration – to team up with Gdańsk University of Technology student Franciszek Bydalek and the UF/IFAS faculty members Patrick Inglett and Todd Osborne to investigate whether struvite could be used to fertilize seagrass beds.
“Coastal ecosystems depend on seagrass beds,” Inglett said. “As they decline, it leads to problems such as declining water quality and the disappearance or migration of marine life to other areas.”

To add to the challenges, current seagrass restoration methods are relatively expensive and unsuccessful compared to other coastal ecosystems. The study indicates that nutrient problems and competition with algae explain these difficulties.
In the study, scientists grew three types of seagrass plots in a simulated setting at the UF Whitney Laboratory for Marine Biosciences. One type received an application of struvite, another received a regular controlled-release fertilizer, and the last received no fertilizer. Two experiments were conducted, testing different fertilizer dosages.

“From both experiments, we found that struvite worked better than controlled-release fertilizer in seagrass growth,” MacDonnell said. “Struvite appears to provide a slower, more consistent release of nutrients into the seagrass.”
According to the researchers, the benefits of using struvite in these efforts extend to environmental sustainability.
“Struvite is potentially a win-win solution for the environment,” Inglett said. “It is removed from wastewater, which reduces impact on downstream ecosystems and does not over-fertilize when used for restoration.”

These downstream effects were investigated in a previous study by another then PhD student. student in the same UF department. John Hallas worked with faculty members from the UF/IFAS North Florida Research and Education Center, Cheryl Mackowiak and Ann Wilkie, to research results from water treatment facilities near the Quincy-based center.
“Recovering struvite from wastewater treatment plants is an effective diversion of these useful nutrients for plant growth, rather than allowing them to enter the landfill,” Mackowiak said.

“It also results in a more useful biosolid product, making the wastewater treatment process more sustainable,” Wilkie added.
MacDonnell explained that sourcing struvite also adds to its sustainability credentials compared to more traditional fertilizers. Phosphorus mining, for example, depletes this finite natural resource and degrades the land.

Potential struvite research is just beginning, predicts MacDonnell. He continued to study herbal restoration and his current role is to work with Osborne as a postdoctoral associate. This work, he says, could include further struvite studies in the future.
“Although the use of struvite in aquatic systems seems very promising, there are not many studies on it in marine restoration projects,” he said, “especially in combination with other restoration techniques”.

Measurements of seagrass growth after struvite application.
Photo credit: Conor MacDonnell.
]]>
Could your body be storing the key to saving the seagrass? | Local News https://imphos.org/could-your-body-be-storing-the-key-to-saving-the-seagrass-local-news/ Thu, 27 Oct 2022 10:00:00 +0000 https://imphos.org/could-your-body-be-storing-the-key-to-saving-the-seagrass-local-news/ Seagrasses are vital to the marine ecosystem, where they provide food, habitat, shelter and other services to humans and aquatic organisms. But while the success of seagrass beds is threatened by a few factors, including human activities like boating, a crystallized version of human waste could be the answer to revitalizing these marine habitats. Urine, […]]]>

Seagrasses are vital to the marine ecosystem, where they provide food, habitat, shelter and other services to humans and aquatic organisms. But while the success of seagrass beds is threatened by a few factors, including human activities like boating, a crystallized version of human waste could be the answer to revitalizing these marine habitats.

Urine, it turns out, includes two key ingredients in plant fertilizers: phosphorus and nitrogen. Even better, wastewater treatment facilities are already treating this abundant resource and creating byproducts that would otherwise be sent to landfill.

In its crystallized form, this byproduct is called struvite, the material applied to seagrass beds in a recent study by scientists at the University of Florida.

“Struvite occurs during the wastewater treatment process because magnesium, ammonia and phosphate are all readily available to form the crystalline byproduct,” said Conor MacDonnell, who conducted the study as PhD student. student in the UF/IFAS Department of Soil, Water, and Ecosystem Sciences, said. “The result is a relatively insoluble and durable compound that is found in wastewater treatment plants.”

This relative insolubility led MacDonnell – who graduated in 2021 and now works as a UF postdoctoral associate studying seagrass restoration – to team up with Gdańsk University of Technology student Franciszek Bydalek and the UF/IFAS faculty members Patrick Inglett and Todd Osborne to investigate whether struvite could be used to fertilize seagrass beds.

“Coastal ecosystems depend on seagrass beds,” Inglett said. “As they decline, it leads to problems such as declining water quality and the disappearance or migration of marine life to other areas.”

To add to the challenges, current seagrass restoration methods are relatively expensive and unsuccessful compared to other coastal ecosystems. The study indicates that nutrient problems and competition with algae explain these difficulties.

In the study, scientists grew three types of seagrass plots in a simulated setting at the UF Whitney Laboratory for Marine Biosciences. One type received an application of struvite, another received a regular controlled-release fertilizer, and the last received no fertilizer. Two experiments were conducted, testing different fertilizer dosages.

“From both experiments, we found that struvite worked better than controlled-release fertilizer in seagrass growth,” MacDonnell said. “Struvite appears to provide a slower, more consistent release of nutrients into the seagrass.”

According to the researchers, the benefits of using struvite in these efforts extend to environmental sustainability.

“Struvite is potentially a win-win solution for the environment,” Inglett said. “It is removed from wastewater, which reduces impact on downstream ecosystems and does not over-fertilize when used for restoration.” These downstream effects were investigated in a previous study by another then PhD student. student in the same UF department. John Hallas worked with faculty members from the UF/IFAS North Florida Research and Education Center, Cheryl Mackowiak and Ann Wilkie, to research results from water treatment facilities near the Quincy-based center.

“Recovering struvite from wastewater treatment plants is an effective diversion of these useful nutrients for plant growth, rather than allowing them to enter the landfill,” Mackowiak said.

“It also results in a more useful biosolid product, making the wastewater treatment process more sustainable,” Wilkie added.

MacDonnell explained that sourcing struvite also adds to its sustainability credentials compared to more traditional fertilizers. Phosphorus mining, for example, depletes this finite natural resource and degrades the land.

Potential struvite research is just beginning, predicts MacDonnell. He continued to study seagrass restoration and his current role is to work with Osborne as a postdoctoral associate. This work, he says, could include further struvite studies in the future.

“Although the use of struvite in aquatic systems seems very promising, there are not many studies on it in marine restoration projects,” he said, “especially in combination with other restoration techniques”.

]]>
How heart failure disrupts the cell’s powerhouse https://imphos.org/how-heart-failure-disrupts-the-cells-powerhouse/ Mon, 24 Oct 2022 17:19:21 +0000 https://imphos.org/how-heart-failure-disrupts-the-cells-powerhouse/ Investigations in Japan have uncovered some molecular mechanisms behind mitochondrial dysfunction in chronic heart failure. Chronic heart failure causes the cell’s power plants to malfunction, in part due to the overconsumption of an important intermediate compound in energy production. Supplementing the diet to compensate for this could prove to be a promising strategy for the […]]]>

Investigations in Japan have uncovered some molecular mechanisms behind mitochondrial dysfunction in chronic heart failure.

Chronic heart failure causes the cell’s power plants to malfunction, in part due to the overconsumption of an important intermediate compound in energy production. Supplementing the diet to compensate for this could prove to be a promising strategy for the treatment of heart failure. The results were published in the journal PNAS by scientists and colleagues from Hokkaido University in Japan.

Mitochondria are small organelles found in almost all cells and are responsible for converting carbohydrates, fats and proteins into energy to fuel biochemical reactions. Chronic heart failure is known to be associated with mitochondrial dysfunction, but how this occurs at the molecular level is still unknown.

A research team consisting of molecular biologist Hisataka Sabe (Hokkaido University), cardiovascular medicine specialists Shingo Takada (Hokkaido University and Hokusho University) and Shintaro Kinugawa (Kyushu University) and their colleagues studied the biochemical processes which occur in mice with chronic heart failure caused by surgically blocking off part of the blood supply to their heart. They specifically looked at heart cells outside the boundaries of dead tissue.

They found a significant reduction in a compound called succinyl-CoA, which is an intermediate in the cell’s tricarboxylic acid cycle. This cycle, which occurs inside the mitochondria, plays an important role in the breakdown of organic molecules to release energy.

Further investigations revealed that this reduction in succinyl-CoA levels was at least partly caused by its overconsumption for heme synthesis, which is essential for mitochondrial oxidative phosphorylation. This latter process is necessary to transfer and synthesize energy transport and storage molecules by the mitochondria.

Adding a compound called 5-aminolevulinate (5-ALA) acid to mice’s drinking water immediately after cutting off the blood supply to part of the heart significantly improved their heart function, treadmill running ability rolling and their survival. At the molecular level, it enhanced the oxidative phosphorylation capacity of heart muscle mitochondria and appeared to restore their succinyl-CoA levels.

Further research is needed to clarify other factors involved in reduced levels of mitochondrial succinyl-CoA in heart failure. For example, scientists have found evidence that succinyl-CoA can also be overused in mitochondria affected by heart failure to break down ketones for energy. But further investigations are needed to understand why this might be happening and if there really is a direct link between the two.

“Our results deepen the understanding of the detailed metabolic changes that occur in chronic heart failure and could contribute to the development of more natural disease prevention and treatment,” the team members say. “Furthermore, a combination of nutritional interventions that can correct the metabolic distortions that occur in chronic heart failure – as this study reveals – and currently used therapeutic drugs could be very effective in treating this disease.”

Source of the story:

Materials provided by Hokkaido University. Note: Content may be edited for style and length.

]]>